<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633513</url>
  </required_header>
  <id_info>
    <org_study_id>LBT-PD-003</org_study_id>
    <nct_id>NCT03633513</nct_id>
  </id_info>
  <brief_title>Parkinson's Disease Inflammatory Biomarker Profiling</brief_title>
  <official_title>Inflammatory Parkinson's Disease (PD) Clinical Biomarker Profiling in T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Longevity Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corporal Michael J. Crescenz VA Medical Center - Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Longevity Biotech</source>
  <oversight_info>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares a comprehensive panel of immunological biomarkers between Parkinson's&#xD;
      disease patients and healthy, environmentally matched participants. This unique study design&#xD;
      provides the ability to control for differences in environment between study subjects. The&#xD;
      goal of this study is to 1) identify a specific set of immunological markers that correlate&#xD;
      with a clinical diagnosis of Parkinson's disease and 2) stratify patients by disease severity&#xD;
      using these same biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson Disease Rating Scale</measure>
    <time_frame>1 hour</time_frame>
    <description>Clinical scoring system to evaluate severity of Parkinson's disease in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-17</measure>
    <time_frame>48 hours</time_frame>
    <description>Proinflammatory cytokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FoxP3</measure>
    <time_frame>48 hours</time_frame>
    <description>Regulatory Tcell marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GM-CSF</measure>
    <time_frame>48 hours</time_frame>
    <description>Cytokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRRK2</measure>
    <time_frame>48 hours</time_frame>
    <description>Leucine rich region kinase 2 protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VPAC2</measure>
    <time_frame>48 hours</time_frame>
    <description>Regulates TH1/TH2 balance of inflammatory system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon gamma</measure>
    <time_frame>48 hours</time_frame>
    <description>Inflammatory cytokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha</measure>
    <time_frame>48 hours</time_frame>
    <description>Inflammatory cytokine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune cell functional analysis</measure>
    <time_frame>1 week</time_frame>
    <description>Performance evaluation of protective immune cells (Tregs) compared to responder immune cells (Tresp)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Clinical diagnosed Parkinson's disease patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caregivers</arm_group_label>
    <description>Environmentally matched healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LBT-3627</intervention_name>
    <description>Immunomodulatory agent</description>
    <arm_group_label>Caregivers</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immunological profiling</intervention_name>
    <description>Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays</description>
    <arm_group_label>Caregivers</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Parkinson's disease and their caregivers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        All Participants&#xD;
&#xD;
          -  Subjects must be willing and able to participate in study&#xD;
&#xD;
          -  Subjects must be willing and able to provide written consent to participate.&#xD;
&#xD;
          -  Subjects must be willing and able to comply with scheduled clinic visits and study&#xD;
             procedures (UPDRS exam, blood draw and complete a questionnaire)&#xD;
&#xD;
          -  Subjects are not currently taking an immunomodulatory (e.g. anti- tumor necrosis&#xD;
             factor (TNF), immunosuppressants/stimulants) agent in the past 90 days&#xD;
&#xD;
          -  No active or recent (&lt; 3 weeks) infection requiring clinical intervention and/or&#xD;
             pharmaceutical treatment or febrile neutropenia within the last week.&#xD;
&#xD;
          -  18-89 years old&#xD;
&#xD;
        Parkinson's Disease Patients&#xD;
&#xD;
          -  Clinical diagnosis of PD by a movement disorders specialist consistent with standard&#xD;
             criteria&#xD;
&#xD;
          -  Able to attend a clinical visit in the 'off' state&#xD;
&#xD;
          -  Hoehn and Yahr stage I-IV&#xD;
&#xD;
        Caregiver Controls&#xD;
&#xD;
        • Individuals without PD who share environmental exposures (i.e. spouses, children,&#xD;
        caregivers or other individuals who frequently spend significant time (&gt;6 hours) in&#xD;
        proximity to the PD subject) OR age and sex matched healthy individuals from general&#xD;
        population&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        All Participants&#xD;
&#xD;
          -  Unstable cardiopulmonary or cerebrovascular disease&#xD;
&#xD;
          -  Renal disease or failure w/ serum creatinine greater than 2.5&#xD;
&#xD;
          -  Severe or unstable depression or other axis I psychopathology&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Prior brain surgery related to PD (DBS, cell implantation, gene therapy, etc.)&#xD;
&#xD;
          -  Severe head injury with evidence of brain injury&#xD;
&#xD;
          -  Essential Thrombocythemia (ET) (&gt;450,000 platelets/mL)&#xD;
&#xD;
          -  Patients currently being treated with any of the following, within the past 5 days:&#xD;
&#xD;
          -  Immunomodulatory agents (e.g. Remicade®, Humira®, Enbrel®) (within the past 90 days)&#xD;
&#xD;
          -  Corticosteroids&#xD;
&#xD;
          -  Probenecid®&#xD;
&#xD;
          -  Coenzyme Q10®&#xD;
&#xD;
          -  Anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Shandler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longevity Biotech, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Shandler, PhD</last_name>
    <phone>215-689-1042</phone>
    <email>scott@longevitybiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Longevity Biotech, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Shandler, Ph.D.</last_name>
      <phone>215-689-1042</phone>
      <email>clinical@longevitybiotech.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://foxtrialfinder.michaeljfox.org/trial/5308/</url>
    <description>Michael J. Fox Trial Finder</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune System</keyword>
  <keyword>Immunology</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

